Table 1.

Serum ANGPTLs change in metabolism-related diseases.

	T2DM	Obesity	NASH/NAFLD	Lipodystrophy
ANGPTL3	↑ in T2DM vs. obese non-T2DM. b	Unchanged b	Non-increased in NAFLD, higher levels in advanced levels of NASH. b ↑ in conditions of metabolic inflammation. b ↓ in lipodystrophic patients in treatment with metreleptin. b	High levels of ANGPTL3 in untreated patients. b Consistent ANGPTL3 reduction in leptin-replacement therapy. b
ANGPTL4	↑ in T2DM vs. obese non-T2DM. b	↑ Obesity vs. normal BMI. b Reflects adipose tissue dysfunction. b	Unchanged b	Unchanged b
ANGPTL8	↑↑ in glycometabolism impairment. b Induced by insulin. a Related with serum LDL-c, TGs and HDL-c inversely. b	Unchanged in case of glycometabolism compensation. b	Associated with grade of lipid accumulation in hepatocytes. a	Associated with grade of lipid accumulation in hepatocytes in leptin deficient mouse. a Unresearched in Human. b

Table Legend: Levels of circulating ANGPTLs in common cardiometabolic diseases. ^a—studies in animal models. ^b—studies in human. Arrows indicate increase (↑) or decrease (↓) of ANGPTLs serum concentration. T2DM (type 2 diabetes mellitus); NAFLD (Non-Alcoholic fatty liver Disease); NASH (Non-Alcoholic Steatohepatitis); BMI (body mass index); TGs (triglycerides); HDL-c (high density lipoprotein cholesterol); LDL-c (low density lipoprotein cholesterol).